Inhibition of the epidermal growth factor receptor increases epxression of genes that stimulate inflammation, apoptosis, and cell attachment

Molecular Cancer Therapeutics

Volumn 4, Issue 4, 2005, Pages 650-658

  Woodworth, Craig D ^a,b   Michael, Evan ^a,d   Marker, Dan ^b   Allen, Sarah ^b   Smith, Laura ^b   Nees, Matthias ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CLARKSON UNIVERSITY   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL ADHESION; CONTROLLED STUDY; DNA MICROARRAY; DNA SYNTHESIS; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BROMODEOXYURIDINE; CELL CYCLE; CELL LINE, TUMOR; COLLAGEN; DNA; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; IMMUNOPRECIPITATION; INFLAMMATION; NF-KAPPA B; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDE PROBES; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA; TYROSINE; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 18044364483     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0238     Document Type: Article

References (57)

1. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
2. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284;31-53.
3. Threadgill DW, Dlugosz AA, Hansen LA, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995;269:230-4.
4. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol 1965;12:394-407.
5. Ando Y, Jensen PJ. Epidermal growth factor and insulin-like growth factor I enhance keratinocyte migration. J Invest Dermatol 1993;100: 633-9.
6. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
7. Kersemaekers AM, Fleuren GJ, Kanter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577-86.
8. Chapman WB, Lorincz AT, Willett GD, Wright VC, Kurman RJ. Epidermal growth factor receptor expression and the presence of human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynecol Pathol 1992;11:221-6.
9. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983;1:511-29.
10. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8;3-9.
11. Modi S, Seidman AD. An update on epidermal growth factor receptor inhibitors. Curr Oncol Rep 2002;4:47-55.
12. Grunwald V, Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer 2002;26:109-64.
13. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003;30:3-11.
14. Lynch TJ, Bell DW, Sardella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
15. Zembutsu H, Ohnishi Y, Daigo Y, et al. Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839. Int J Oncol 2003;23:29-39.
16. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-500.
17. Hollywood E. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. Semin Oncol Nurs 2002;18:30-5.
18. Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265: 1093-5.
19. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997;3:2099-106.
20. 1 arrest in prostatic cancer cell line DU145. Cancer Res 1996;56:3666-9.
21. Kari C, Chan TO, Roche de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003;63:1-5.
22. Wang F, Weaver VM, Petersen OW, et al. Reciprocal interactions between β1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci U S A 1998;95:14821-6.
23. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30.
24. Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, et al. Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinacytes. Cancer Res 1997;57:3741-50.
25. Yarwood SJ, Woodgett JR. Extracellular matrix composition determines the transcriptional response to epidermal growth factor receptor activation. Proc Natl Acad Sci U S A 2001;98:4472-7.
26. McCance DJ, Kopan R, Fuchs E, Laimins LA. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A 1988;85:7169-73.
27. Woodworth CD, Bowden PE, Doniger J, et al. Characterization of normal human exocervical epithelial cells immortalized in vitro by papillomavirus types 16 and 18 DNA. Cancer Res 1988;48:4620-8.
28. Woodworth CD, McMullin E, Iglesias M, Plowman GD. Interleukin 1 α and tumor necrosis factor α stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci U S A 1995;92: 2840-4.
29. Woodworth CD, Cheng S, Simpson S, et al. Recombinant retroviruses encoding human papillomavirus type 18 E6 and E7 genes stimulate proliferation and delay differentiation of human keratinocytes early after infection. Oncogene 1992;7:619-26.
30. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J Virol 2001;75:4283-96.
31. Woodworth CD, Gaiotti D, Michael E, Hansen L, Nees M. Targeted disruption of the epidermal growth factor receptor inhibits development of papillomas and carcinomas from human papillomavirus-immortalized keratinocytes. Cancer Res 2000;60:4397-402.
32. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
33. Baer C, Nees M, Breit S, et al. Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer 2004;110:687-94.
34. Ebert AD, Wechselberger C, Martinez-Lacaci I, Bianco C, Weitzel HK, Salomon DS. Expression and function of EGF-related peptides and their receptors in gynecological cancer-from basic science to therapy. J Recept Signal Transduct Res 2000;20:1-46.
35. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
36. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
37. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37 Suppl 4:S3-8.
38. Flanagan K, Kaufman HL. Chemokines and cancer. Cancer Invest 2002;20:825-34.
39. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003;163:303-12.
40. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 2003;17:23-8.
41. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
42. Grone A. Keratinocytes and cytokines. Vet Immunol Immunopathol 2002;88:1-12.
43. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002;2:59-65.
44. Woodworth CD. HPV innate immunity. Front Biosci 2002;7: d2058-71.
45. Doan T, Herd K, Street M, et al. Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. J Virol 1999;73:6166-70.
46. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
47. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor κ B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 2000;97:8542-7.
48. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
49. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988;80:1605-11.
50. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-33.
51. Jost M, Class R, Kari C, Jensen PJ, Rodeck U. A central role of Bcl-X(L) in the regulation of keratinocyte survival by autocrine EGFR ligands. J Invest Dermatol 1999;112:443-9.
52. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis: anoikis". Apoptosis 2002;7:247-60.
53. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6:4823-30.
54. Pinkes J, Leder P. MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition. Cancer Res 2002;62:4781-90.
55. Al Moustafa AE, Yansouni C, Alaoui-Jamali MA, O'Connor-McCourt M. Up-regulation of E-cadherin by an anti-epidermal growth factor receptor monoclonal antibody in lung cancer cell lines. Clin Cancer Res 1999;5:681-6.
56. Penar PL, Khoshyomn S, Bhushan A, Tritton TR. inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 1997;40:141-51.
57. Fujimura M, Hidaka T, Saito S. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells. Clin Cancer Res 2002;8:2448-54.